T-NeuroDx Appoints Dr. Michael Reed as CEO to Drive Investment and Growth
T-NeuroDx, a pioneering company developing diagnostic tools for Alzheimer’s disease using atypical immune cells, today announced the immediate appointment of Michael Reed, Ph.D., as its new Chief Executive Officer and Chairman of the Board of Directors. The move is part of a strategic restructuring to…
T-NeuroDx Secures $500,000 NIH Grant to Advance Novel Alzheimer’s Disease Blood Biomarker Research
T-NeuroDx, a pioneering diagnostics company dedicated to developing innovative solutions for detecting neurodegenerative diseases, is pleased to announce that it has received a $500,000 grant from the National Institutes of Health (NIH). This significant funding will support a transformative project aimed at expanding biomarker validation…
TrilliumBiO and T-NeuroDx Announce Strategic Collaboration to Commercialize Blood-Based Biomarkers for Alzheimer’s Disease
TrilliumBiO, a leader in biomarker discovery and precision diagnostics, today announced a strategic collaboration with T-NeuroDx, a pioneering diagnostics company dedicated to developing innovative solutions for detecting neurodegenerative diseases, to advance the development of blood-based biomarker diagnostics for Alzheimer’s disease. This partnership brings together TrilliumBiO’s…
T-NeuroDx to Present Advances in Blood Test for Early Alzheimer’s Detection at Major Conference
T-NeuroDx, a company pioneering new diagnostic tools that use abnormalities in the immune system to detect Alzheimer’s Disease, will present its latest research at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto, Canada, from July 27–31. Dr. Christopher Wheeler, the company’s Chief Science Officer,…
T-NeuroDx and Beckman Coulter Life Sciences to Collaborate on Early Alzheimer’s Disease Research
T-NeuroDx, a leading biotechnology company dedicated to developing innovative diagnostics for neurodegenerative diseases, announced today a collaboration with Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation. The two companies will collaborate on biomarker research aimed at early Alzheimer’s disease detection. The…
T-Neuro Pharma Welcomes Renowned Alzheimer’s Researcher Dr. Jeffrey Cummings as Chair of Scientific Advisory Board
T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, announced today the appointment of Dr. Jeffrey Cummings, MD, ScD as Chair of its Scientific Advisory Board (SAB). Dr. Cummings, a world-renowned expert in Alzheimer’s disease research and clinical trials, brings…
T-Neuro Pharma Announces Publication of Groundbreaking Alzheimer’s Research in Prestigious Journal
ALBUQUERQUE, New Mexico — T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative diagnostics and therapeutics for neurodegenerative diseases, announced the publication of a landmark research article in Proceedings of the National Academy of Sciences(PNAS), a peer-reviewed journal of the National Academy of Sciences….
CEO Making Strides in the Diagnosis of Alzheimer’s Disease Named One of the Three Fellows for LANL’S Prestigious “LEEP” Program
Los Alamos National Laboratory recently launched the New Mexico Lab-Embedded Entrepreneur Program (New Mexico LEEP) in January of 2022. Through this program, entrepreneurs are provided a two-year fellowship that focuses on technical solutions to society’s largest concerns. These solutions, also referred to as “deep tech”,…
T-Neuro Pharma takes a new approach to Alzheimer’s Disease diagnosis and treatment
ALBUQUERQUE — While the vast majority of Alzheimer’s Disease (AD) clinical trials have focused on decreasing beta-amyloid (the sticky protein fragment that gums up the brain and kills its cells) 99.6% of these trials have failed. The 0.4% that succeeded only treat symptoms, but do…